At a glance
ClinicalIndex Comparison RecordN/ACompleted· 183 enrolled
Drug / intervention
t:slim X2 insulin pump with Control-IQ technology 1.5device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
In Brief
A clinical study evaluating t:slim X2 insulin pump with Control-IQ technology 1.5 for Type 1 Diabetes. Completed, enrolled 183 participants across 13 sites.
Detailed Summary
Prospective, multi-center, single-arm study in adults and children ages 6 to 80 with type 1 diabetes to evaluate the safety of Lyumjev with Control-IQ technology to achieve labeling updates for Lyumjev and the t:slim X2 insulin pump.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsEli Lilly and Company, Jaeb Center for Health Research
Timeline
N/ACompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionAug 2023
TodayJul 2026
First PostedJun 3, 2022
Enrollment StartAug 31, 2022
Primary CompletionAug 2, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.1 years ago
Interventions
t:slim X2 insulin pump with Control-IQ technology 1.5device
t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.